Page 8 - Pharma

Cardiac, vitamin drugs see pharma sales rebound with 4.5% growth in Sept

Industry says fresh prescriptions are picking up

Higher sales in domestic market, lower costs bode well for Glenmark

The other trigger for the stock is the cost savings from lower investments in R&D and fund raising for innovation research

Kochi firm gets nod to test India's first novel molecule for Covid-19

PNB Vesper's drug developed from 12 years of research for small-cell lung cancer (for which it is under trial) has shown positive response in Covid-19, the firm claims

AstraZeneca Pharma India Q1 net profit declines 13 pc at Rs 18.63 cr

Drug firm AstraZeneca Pharma India on Monday reported a 13.38 per centdecline in its net profit to Rs 18.63 crore for the quarter ended June. The company had posted a net profit of Rs 21.51 crore for the corresponding period of the previous fiscal, AstraZeneca Pharma India said in a BSE filing. Revenue from operations stood at Rs 193.57 crore for the quarter under consideration. It was Rs 204.56 crore for the same periodyear ago, it added. The board of directors has declared an interim dividend of Rs 2 per equity share for the financial year 2020-21, the filing said. Shares ofAstraZeneca Pharma India were trading at Rs3,381.65per scrip on BSE, up 1.50 per cent over previous close.

Unichem gets USFDA nod for generic version of tolterodine tartrate tablets

The tolterodine tartrate tablets are generic versions of Pfizer Inc's DETROL tablets

Why are cheaper Covid-19 drugs not being promoted, asks Parliamentary panel

Cutting across party lines, the committee members questioned why expensive medicines were often being recommended for Covid-19 treatment

India's Sovereign Pharma dispatches first batch of remdesivir to Cipla

Privately held Sovereign Pharma is manufacturing and packaging Cipla's remdesivir version

First Covid-19 vaccine to reach phase-1 trial is safe, say researchers

Several teams across the world are in a race to develop a vaccine for coronavirus infection

Coronavirus: Eli Lilly starts testing; Gilead drug shows positive signs

Lilly said it currently does not anticipate shortages for any of its medicines, including baricitinib

Glenmark gets tentative nod from USFDA for generic type-2 diabetes tablets

The product is a generic version of AstraZeneca AB's Farxiga tablets

Here's how common mental shortcuts can cause major physician errors

In health care, unconscious biases can lead to disparate treatment of patients and can affect whether similar patients live or die

Govt asks pharma groups to ensure companies follow ethical practices

The DoP drafted the UCPMP has been voluntarily followed by drug firms since 2015., however, the code is not mandatory

Drugmakers slash prices to be eligible for China's bulk-buy program

Sale prices of over 100 types of commonly used drugs are on average about 17 to 18 times of their manufacturing costs, the statement said

Ready with the innovation edge

Global capability centres will drive innovation for the global enterprise

Q3 results preview: US regulatory overhang on earnings of pharma firms

The US is Indian pharma's largest export market and Indian drugmakers account for a little over 30 per cent of generic drugs sold in that country

Gene therapy to conquering hepatitis C: A decade of medical breakthroughs

Putting aside prices for a moment, it's been an exciting period for medical progress

NITI Aayog plans to bring all medical devices under one regulatory regime

The NITI Aayog has proposed to do away with the need to have manufacturing licences to register a medical device

Pharma sector likely to grow at 10-12% during FY19-22, outlook stable: Icra

Icra cited abating headwinds from pricing pressure in the US, stable growth for the Indian market driven by increasing healthcare spending

Price hike, at last

Govt should not control drug prices

Ceiling prices of 21 key medicines raised by 50%; NPPA invokes DPCO 2013

The prices of APIs have gone up in the range of 5-88%